Patients with chronic myeloid leukemia (CML) who underwent multilevel intervention had greater odds of staying adherent to tyrosine kinase inhibitor (TKI) treatment, the TAKE-IT study reported.1
The pilot trial followed a quasi-experimental pre-post intervention design and included a convenience sample of 58 CML patients who received TKI treatment across 4 different centers in Israel. Patients were aged a median of 60.5 years, and most patients (62%) received TKI treatment in the first-line setting.
Study researchers determined patient adherence to TKIs through electronic monitoring. Patients were electronically monitored for 4 months to determine baseline adherence before intervention and then for 3 months after intervention. The intervention was a multilevel approach, including training of health care providers and use of behavior change techniques with patients, such as motivational interviewing and feedback on electronic monitoring results.
At baseline, patients had a median adherence rate of 97.5% (range, 48%-100%). After intervention, the odds of a patient taking the TKI daily as prescribed were 58% greater compared with baseline (odds ratio = 1.58; 95% confidence interval [CI], 1.16-2.15). Overall, adherence among patients increased by 1.5% (95% CI, 0.1-2.8; P = .04). In a subset of 10 patients who had adherence levels below 90% at baseline, however, adherence increased from a 71.2% average adherence before intervention to an average adherence of 79.6% after intervention, representing an 8.5% increase in adherence (P = .04).
“TKI adherence improved with our pilot intervention, mainly in patients with suboptimal baseline adherence,” the study authors wrote.
- Leader A, Benyamini N, Gafter-Gvili A, et al. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A quasi-experimental pre-post intervention multicenter pilot study. Clin Lymphoma Myeloma Leuk. 2018;18(11):e449-e461. doi: 10.1016/j.clml.2018.06.026